iCura Diagnostics
- Company typePrivate
- Founded2020
- HeadquartersMalvern, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
iCura Diagnostics firmographics
Firmographics- Name
- iCura Diagnostics
- Legal name
- iCura Diagnostics Inc.
- Website
- https://icuradx.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
iCura Diagnostics industry classification
Industry- Product category
- Diagnostic Laboratory Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)
- akta.pro secondary industries
- Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Anatomic Pathology & Histopathology (Trial Support) (HLAGAEAC)
Keywords
Where iCura Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Malvern
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
iCura Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Digital Pathology Services: Laboratory diagnostic services including histopathology, digital pathology, whole slide imaging, multiplex IF/IHC, and image analysis for research and clinical trial support.
- Genomics Services: NGS, digital PCR, qPCR, and real-time PCR services including tumor profiling, targeted cancer panels, spatial transcriptomics, and whole transcriptome sequencing.
- Clinical Trial Logistics: Lab testing, sample management, site training, sample handling, and transportation support for clinical trial studies.
- Circulating Tumor Cell (CTC) Services: FDA-approved platform for CTC detection and analysis supporting clinical trials and medical diagnoses.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Professional Services - Custom Quotes |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
iCura Diagnostics product offering
Product offeringCore offering
iCura Diagnostics is a CLIA/CAP certified diagnostic laboratory that delivers spatial biology and digital pathology services to pharmaceutical, biotechnology, and academic clients. Its core offerings include histopathology/digital pathology, multiplex immunofluorescence (mIF) with custom panels, genomics services (NGS, digital PCR, qPCR), and clinical trial logistics. The laboratory operates high-throughput instrumentation such as the Akoya PhenoImager HT, Leica BOND RX, NextSeq 2000, and Qiagen Qiacuity ndPCR to support precision diagnostics and drug development.
Product overview
iCura Diagnostics operates as a CLIA/CAP certified diagnostic laboratory offering a comprehensive suite of spatial biology and digital pathology services. The company provides end-to-end solutions from sample processing to interpretation, combining Histopathology/Digital Pathology, Multiplex Immunofluorescence (mIF), and Genomics Services (NGS, digital PCR) with Clinical Trial Logistics support. Their technology stack includes Akoya PhenoImager HT, Leica BOND RX, NextSeq 2000, and Qiagen Qiacuity platforms. They offer validated Phenocode Panels and specialty services like Circulating Tumor Cell analysis and the 6-Plex 7-Color Lung Cancer/Melanoma Panel. The portfolio enables spatial phenotyping, biomarker discovery, and precision diagnostics for pharmaceutical companies and research institutions.
Differentiator
Problem solved
Functional benefit
Products and services
- Histopathology / Digital Pathology End-to-end digital pathology services providing quantitative analysis for IHC, FISH, CISH, RNAScope, and custom assays to support patient screening and clinical research for pharmaceutical, biotech, and academic clients.
- Multiplex Immunofluorescence (mIF) Custom multiplex immunofluorescence panels including Akoya MOTiF lung panel, melanoma kit, TME panels, Hodgkin's Lymphoma panel, glioblastoma microenvironment panel, and custom panel design for spatial biology analysis.
- Genomics Services Comprehensive genomics solutions including NGS, digital PCR, qPCR, real-time PCR, tumor profiling, targeted cancer panels, gene therapy analysis, spatial transcriptomics, and whole transcriptome sequencing, with custom pipelines for AI-enabled biomarker studies.
- Clinical Trial Logistics Streamlined laboratory testing and sample management support including detailed lab manuals, site training, sample handling, and transportation for clinical trial studies.
- Circulating Tumor Cell (CTC) Services FDA-approved platform for detection and analysis of circulating tumor cells supporting clinical trial efficacy assessment, disease progression monitoring, and personalized medicine approaches.
- 6-Plex 7-Color Lung Cancer and Melanoma Panel Validated multiplex panel for simultaneous detection and quantification of key genetic alterations associated with lung cancer and melanoma using 7-color fluorescence technology.
Companies that use iCura Diagnostics
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
iCura Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature9 records
iCura Diagnostics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AKOYA BiosciencescoreiCura Diagnostics is AKOYA Biosciences' first-ever Fully Qualified Service Provider Partner. This partnership provides access to cutting-edge spatial biology solutions including multiplexed immunofluorescence (mIF) and imaging technologies for comprehensive tissue analysis. The collaboration enables deeper insights into cellular interactions and biomarker expression patterns, with access to AKOYA's extensive network of experts and resources for knowledge-sharing and innovation.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
iCura Diagnostics competitors and assessment
Company assessmentDirect peers
- Flagship Biosciences: Specialty CRO providing digital pathology and quantitative IHC image analysis services to pharma/biotech, with comparable tissue-based biomarker offerings and clinical trial support focus. Direct overlap with iCura's histopathology and mIF stack.
- CellCarta Precision Medicine: Global CRO offering histopathology, multiplex immunofluorescence (IHC/IF), digital pathology, and spatial biology services for pharma clinical trials. Closest large-scale peer to iCura's full-service tissue biomarker business.
- Discovery Life Sciences: HudsonAlpha-affiliated biospecimen and biomarker lab providing tissue procurement, IHC, genomics, and bioanalytical services for pharma research – directly comparable in CLIA-certified lab service offerings.
- NeoGenomics: Oncology-focused clinical and pharma services lab operating in anatomic pathology, IHC, molecular and spatial biomarker testing. Larger competitor for clinical trial biomarker work and pharma services revenue.
- Propath: Anatomic pathology reference lab providing IHC, molecular, and specialty diagnostics services for clinicians, hospitals, and pharma clients. Comparable mid-sized specialty pathology lab serving similar end-markets.
Broad incumbents
- Akoya Biosciences: Instrument/platform vendor for iCura's core PhenoImager multiplex IF technology; also operates its own BioPharma services arm. Comparable as both technology supplier and potential internal-service competitor.
- Laboratory Corporation of America (LabCorp): Global clinical lab and CRO offering anatomic pathology, genomics, and clinical trial central lab services. Indirect big-cap competitor for pharma services contracts that iCura targets.
- Quest Diagnostics: Large clinical laboratory offering anatomic pathology, molecular diagnostics, and advanced testing services across the US. Provides a reference point for scale and range in lab diagnostics market.
Emerging players
- Personalis: Molecular diagnostics and spatial biology lab serving pharma oncology trials with NGS and tissue-based assays. Comparable in serving biopharma biomarker needs, but with stronger molecular sequencing emphasis vs. iCura's tissue focus.
- PathAI: AI-driven pathology company with both diagnostic products and pharma services for digital pathology and biomarker quantification. Overlap in image analysis, AI, and pharma partnerships targeting spatial biology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
iCura Diagnostics social profiles
Digital presenceiCura Diagnostics compliance and trust
Trust signalCompliance3 records
iCura Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
iCura Diagnostics leadership team
Management profileNumber of profiles
Profiles1 record
iCura Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iCura Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iCura Diagnostics
What does iCura Diagnostics do?
iCura Diagnostics is a CLIA/CAP certified diagnostic laboratory that delivers spatial biology and digital pathology services to pharmaceutical, biotechnology, and academic clients. Its core offerings include histopathology/digital pathology, multiplex immunofluorescence (mIF) with custom panels, genomics services (NGS, digital PCR, qPCR), and clinical trial logistics. The laboratory operates high-throughput instrumentation such as the Akoya PhenoImager HT, Leica BOND RX, NextSeq 2000, and Qiagen Qiacuity ndPCR to support precision diagnostics and drug development.
Is iCura Diagnostics a public or private company?
iCura Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was iCura Diagnostics founded?
iCura Diagnostics was founded in 2020. It employs 1 to 10 people.
Where is iCura Diagnostics based?
iCura Diagnostics is headquartered in Malvern, United States, in the North America region.
How does iCura Diagnostics make money?
Four revenue lines are on record. Digital Pathology Services are the primary driver. The others are genomics Services, clinical Trial Logistics and circulating Tumor Cell (CTC) Services.
Who are iCura Diagnostics's main competitors?
Direct peers on record are Flagship Biosciences, CellCarta Precision Medicine, Discovery Life Sciences, NeoGenomics and Propath. Broad incumbents are Akoya Biosciences, Laboratory Corporation of America (LabCorp) and Quest Diagnostics. Emerging players are Personalis and PathAI.
Does iCura Diagnostics have an API?
No public API is recorded for iCura Diagnostics.
What industry is iCura Diagnostics in?
iCura Diagnostics's product category is Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology), with a secondary code of HLAHAAAE, Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics). Its NAICS code is 621511 and its SIC code is 8071.